Another of the targeted immunotherapy approaches is the use of immune checkpoint inhibitors, such as anti-CTLA-4 (e.g., ipilimumab) and anti-PD-1/PD-L1 (e.g., nivolumab, pembrolizumab), which increase the population of T cells beneficial for destroying cancer cells, as well as the invention of modified CAR-T T cells, which recognize tumor antigens and activate upon contact with them, leading to the destruction of pathological cells [9,10]. Here, CD274 is linked to neoplasm.